

Generation of gene-engineered T cells

T cell transduction process

Application

Fully automated labelling, enrichment, activation, transduction and expansion of human T cells from patient material for production of gene-engineered T cells.

This application sheet gives an overview of the specifications and material to perform the T cell transduction (TCT) process. Furthermore, it provides an overview of the setup for the tubing set, general workflow and performance data.

Specifications

Process name: T cell transduction process

Selection capacity: up to 3×10^9 cells

Sample volume

for selection: 50-280 mL

TransAct™

stimulation capacity: 1×10^8 cells $(0.2-2 \times 10^8)$ **Expansion capacity:** maximum 2×10^7 cells/mL

Final product

elution volume: 100 mL

Process time: 8–14 days

Materials required*:

Consumables	Amount required
CliniMACS Prodigy®	1 piece
CliniMACS Prodigy TS 520	1 set
CliniMACS® PBS/EDTA Buffer	1 bag
TexMACS™ GMP Medium	3×2 L bags
CliniMACS CD4 Reagent	1 vial
CliniMACS CD8 Reagent	1 vial
MACS® GMP T Cell TransAct	1 vial
MACS GMP Recombinant Human IL-7	3 vials
MACS GMP Recombinant Human IL-15	3 vials

Additional materials	Amount required
Triple sampling adaptor	1 piece
Transfer bag 150 mL	1 bag
Luer/Spike Interconnector	1 piece
MACS GMP Vectofusin-1*	1 vial
Transfer bag 1000 mL	1 bag


Additional equipment and materials
Sterile docking device
Cell counter
Flow cytometer
Syringes and hypodermic needles
Human serum albumin
Final formulation buffer
Human AB serum

^{*}Please discuss your specific requirements with your Miltenyi Biotec representative.


Process overview

Tubing set installation and priming Pre-process Connection of starting material to tubing set				
T cell enrichment	Red blood cell reduction T cell enrichment (CD4/CD8)			
Activation	Stimulation of T cells with T Cell TransAct™			
Viral transduction	Lentiviral or retroviral (+ Vectofusin®-1) transduction			
Cell expansion	Expansion in TexMACS™ Medium with IL-7 and IL-15			
Cell harvest and final formulation	Cells washed and harvested in 100 mL of buffer			
Post-process	Tubing set deinstallation			
8–14 days for total process				

Principle of the T cell transduction process on the CliniMACS Prodigy®



CliniMACS Prodigy® TS 520 setup



Performance data

			Final product					
	Starting product CD4 ⁺ and CD8 ⁺ T cells (%)	Isolated CD4 ⁺ and CD8 ⁺ T cells (%)	CD4 ⁺ and CD8 ⁺ T cells (%)	CAR+ T cells (%)	Viability (%)	CAR ⁺ T cell number (×10 ⁹)		
Performance data of healthy donor or patient derived material								
Healthy (n=9)	72%±11%	83%±9%	91%±5%	34%±12%	90%±4%	1.4±0.7		
Patient (n=5)	23%±21%	55%±9%	88%±7%	36%±18%	88%±7%	1.0±0.4		
Performance data of healthy donor with or without human AB serum (3%) for culture								
With (n=8)	58%±17%	82%±14%	92%±3%	36%±9%	93%±3%	1.6±0.3		
Without (n=8)	60%±15%	87%±7%	94%±6%	43%±12%	93%±3%	2.9±1.3		

References

- Lock, D. and Mockel-Tenbrinck, T. et al. (2017) Human Gene Therapy 28(10): 914–925.
 Mock, U. et al. (2016) Cytotherapy 18(8): 1002–11.



Miltenvi Biotec B.V. & Co. KG

Friedrich-Ebert-Straße 68 51429 Bergisch Gladbach Germany Phone +49 2204 8306-0 Fax +49 2204 85197 macsde@miltenyi.com

Miltenyi Biotec Inc.

2303 Lindbergh Street Auburn, CA 95602-9562, USA Phone 800 FOR MACS Phone +1 530 888 8871 Fax +1 877 591 1060 macsus@miltenyi.com Miltenyi Biotec Australia Pty. Ltd. Phone +61 2 8877 7400 macsau@miltenyi.com

Miltenyi Biotec B.V.
(Benelux)
macsnl@miltenyi.com
Customer service
The Netherlands
Phone 0800 4020120
Customer service Belgium
Phone 0800 94016
Customer service Luxembourg
Phone 800 24971

Miltenyi Biotec Technology & Trading (Shanghai) Co., Ltd. (P.R. China)

Phone +86 21 6235 1005 macscn@miltenyi.com

Miltenyi Biotec SAS (France) Phone +33 1 56 98 16 16 macsfr@miltenyi.com

Miltenyi Biotec S.r.l. (Italy) Phone +39 051 6 460 411 macsit@miltenyi.com

Miltenyi Biotec K.K. (Japan) Phone +81 3 5646 8910 macsjp@miltenyi.com Miltenyi Biotec Norden AB (Nordics and Baltics) macsse@miltenyi.com
Customer service Sweden Phone 0200 111 800
Customer service Denmark Phone 80 20 30 10
Customer service
Norway, Finland, Iceland, and Baltic countries

Miltenyi Biotec Asia Pacific Pte Ltd (Singapore) Phone +65 6238 8183

Phone +65 6238 8183 macssg@miltenyi.com

Phone +46 46 280 72 80

Miltenyi Biotec Korea Co., Ltd. (South Korea)

Phone +82 2 555 1988 macskr@miltenyi.com

Miltenyi Biotec S.L. (Spain) Phone +34 91 512 12 90 macses@miltenyi.com

Miltenyi Biotec Swiss AG (Switzerland)

Phone +41 32 623 08 47 macsch@miltenyi.com

Miltenyi Biotec Ltd. (UK) Phone +44 1483 799 800 macsuk@miltenyi.com

www.miltenyibiotec.com

 $Miltenyi\ Biotec\ provides\ products\ and\ services\ worldwide.\ Visit\ \textbf{www.miltenyibiotec.com/local}\ to\ find\ your\ nearest\ Miltenyi\ Biotec\ contact.$

Unless otherwise specifically indicated, Miltenyi Biotec products and services are for research use only and not for therapeutic or diagnostic use. MACS® GMP Products are for research use and ex vivo cell culture processing only, and are not intended for human in vivo applications. For regulatory status in the USA, please contact your local representative. MACS GMP Products are manufactured and tested under a quality system certified to ISO 13485 and are in compliance with relevant GMP guidelines. They are designed following the recommendations of USP <1043> on ancillary materials. The CliniMACS® System components, including Reagents, Tubing Sets, Instruments, and PBS/EDTA Buffer, are designed, manufactured and tested under a quality system certified to ISO 13485.

In the EU, the CliniMACS System components are available as CE-marked medical devices for their respective intended use, unless otherwise stated. The CliniMACS Reagents and Biotin Conjugates are intended for *in vitro* use only and are not designated for therapeutic use or direct infusion into patients. The CliniMACS Reagents in combination with the CliniMACS System are intended to separate human cells. Miltenyi Biotec as the manufacturer of the CliniMACS System does not give any recommendations regarding the use of separated cells for therapeutic purposes and does not make any claims regarding a clinical benefit. For the manufacturing and use of target cells in humans the national legislation and regulations – e.g. for the EU the Directive 2004/23/EC ("human tissues and cells"), or the Directive 2002/98/EC ("human blood and blood components") – must be followed. Thus, any clinical application of the target cells is exclusively within the responsibility of the user of a CliniMACS System.

In the US, the CliniMACS CD34 Reagent System, including the CliniMACS Plus Instrument, CliniMACS CD34 Reagent, CliniMACS Tubing Sets TS and LS, and the CliniMACS PBS/EDTA Buffer, is FDA approved as a Humanitarian Use Device (HUD), authorized by U.S. Federal law for use in the treatment of patients with acute myeloid leukemia (AML) in first complete remission. The effectiveness of the device for this indication has not been demonstrated. Other products of the CliniMACS Product Line are available for use only under an approved Investigational New Drug (IND) application, Investigational Device Exemption (IDE), or FDA approval. CliniMACS GMP MicroBeads are for research use only and not for human therapeutic or diagnostic use. CentriCult, CliniMACS, CliniMACS, CliniMACS, the Miltenyi Biotec logo, TexMACS, and TransAct are registered trademarks or trademarks of Miltenyi Biotec and/or its affiliates in various countries worldwide. Vectofusin is a registered trademark of Genethon. Copyright © 2020 Miltenyi Biotec and/or its affiliates. All rights reserved.